BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16851048)

  • 1. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
    Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
    J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
    Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
    J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
    Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
    Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
    Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
    Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
    Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
    Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
    Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
    Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.
    Ode H; Matsuyama S; Hata M; Neya S; Kakizawa J; Sugiura W; Hoshino T
    J Mol Biol; 2007 Jul; 370(3):598-607. PubMed ID: 17524421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.